Vaccine value profile for Chikungunya

Ximena Flandes, Clairissa A. Hansen, Sunil Palani, Kaja Abbas, Cate Bennett, William Perea Caro, Raymond Hutubessy, Kanat Khazhidinov, Philipp Lambach, Clara Maure, Caroline Marshall, Diana P. Rojas, Alexander Rosewell, Sushant Sahastrabuddhe, Marta Tufet, Annelies Wilder-Smith, David W.C. Beasley, Nigel Bourne, Alan D.T. Barrett

Research output: Contribution to journalArticlepeer-review


Chikungunya virus (CHIKV) a mosquito-borne alphavirus is the causative agent of Chikungunya (CHIK), a disease with low mortality but high acute and chronic morbidity resulting in a high overall burden of disease. After the acute disease phase, chronic disease including persistent arthralgia is very common, and can cause fatigue and pain that is severe enough to limit normal activities. On average, around 40% of people infected with CHIKV will develop chronic arthritis, which may last for months or years. Recommendations for protection from CHIKV focus on infection control through preventing mosquito proliferation. There is currently no licensed antiviral drug or vaccine against CHIKV. Therefore, one of the most important public health impacts of vaccination would be to decrease burden of disease and economic losses in areas impacted by the virus, and prevent or reduce chronic morbidity associated with CHIK. This benefit would particularly be seen in Low and Middle Income Countries (LMIC) and socio-economically deprived areas, as they are more likely to have more infections and more severe outcomes. This ‘Vaccine Value Profile’ (VVP) for CHIK is intended to provide a high-level, holistic assessment of the information and data that are currently available to inform the potential public health, economic and societal value of vaccines in the development pipeline and vaccine-like products. This VVP was developed by a working group of subject matter experts from academia, non-profit organizations, public private partnerships, and multi-lateral organizations. All contributors have extensive expertise on various elements of the CHIK VVP and collectively aimed to identify current research and knowledge gaps. The VVP was developed using only existing and publicly available information.

Original languageEnglish (US)
StateAccepted/In press - 2023


  • Chikungunya
  • Vaccine
  • Vaccine value
  • Virus infection

ASJC Scopus subject areas

  • Molecular Medicine
  • General Immunology and Microbiology
  • General Veterinary
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'Vaccine value profile for Chikungunya'. Together they form a unique fingerprint.

Cite this